KZKaitlyn Zenner

Kaitlyn Zenner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaitlyn Zenner has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Orbital Lymphatic Malformations Are Associated With Intracranial Vascular Anomalies

    by Kelsey A. Loy, Jennifer Siu, Clare Richardson, J. Nathaniel Perkins, Kaitlyn Zenner, Kevin Koo, Francisco Perez, James Bennett, Randall Bly, Danial K. Hallam, et al.

    Objectives: Orbital lymphatic malformations (OLMs) are a rare type of lymphatic malformation involving the soft tissues within the bony orbit. OLMs present specific treatment challenges and cause significant morbidity. The contribution of pathologic genetic variants and potential association of intracranial vascular anomalies with OLMs has yet to be described. We hypothesized that (1) OLMs are indicators of underlying cerebrofacial venous metameric syndrome (CVMS) and are associated with intracranial vascular anomalies, and (2) OLMs are caused by PIK3CA variants and are candidates for targeted medical therapy. Methods: Retrospective case review was performed for patients with OLMs treated at a single institution from 2000 to 2025. Diagnosis of CVMS was made via magnetic resonance imaging (MRI) based on established criteria of segmental distribution of ocular, facial, and cerebral vascular malformations. Symptoms, MRI and genetic findings, and management are described. Results: Seven of 412 patients with head and neck lymphatic malformations had OLM. Common symptoms included eye swelling ( n = 7), ptosis ( n = 3), and headache ( n = 5). All patients were diagnosed with CVMS on MRI. All patients underwent surgical resection and were candidates for targeted medical therapy after tissue‐based DNA sequencing revealed “hotspot” PIK3CA variants p.E542K ( n = 4) and p.H1047R ( n = 3). Five patients were started on alpelisib, resulting in symptom improvement at 6 months of treatment. Conclusion: OLMs were associated with intracranial vascular anomalies, meeting radiographic criteria for CVMS. All patients had “hotspot” PIK3CA variants on tissue‐based genetic testing. Screening for intracranial vascular anomalies and targeted medical therapy with PI3K/AKT/mTOR pathway inhibitors should be considered in OLM management. Level of Evidence: 3.


  • Open Access

    Rethinking drain protocols in pediatric thyroidectomy

    by Kaitlyn Zenner, Ashley L. Soaper, Charles M. Myer, Michael J. Rutter, Matthew M. Smith

  • Open Access

    Vascular Anomalies Review of the Head and Neck for Physicians in Training

    by Caleb M. Allred, Kaitlyn B. Zenner, Juliana Bonilla-Velez

    A basic understanding of vascular anomalies will aid physicians-in-training as they seek to properly diagnose and determine interventions for these patient presentations. The aim of this review is to create a resource for physicians in training that encompasses the most important clinical aspects of vascular anomalies. Vascular anomalies of the head and neck are divided into two categories: vascular tumors and vascular malformations. This review will first describe vascular tumors followed by vascular malformations. This review discusses major pathology found in both categories of vascular anomaly. Vascular anomalies are frequently found in pediatric populations and can persist into adulthood, making it important for trainees to identify them on physical exam. This developing field seeks to improve form, function, and quality of life for patients with vascular anomalies and often requires a multidisciplinary approach (i.e., otolaryngology, dermatology, genetics, plastic surgery, interventional radiology). Various medical and surgical treatment options are available. A basic knowledge of these anomalies will allow for accurate, early diagnosis and appropriate intervention which can ultimately improve patient outcomes. Search Strategy and Selection Criteria: The MEDLINE/PubMed database was searched for primary research and reviews discussing various vascular anomalies which include infantile hemangioma, congenital hemangioma, pyogenic granuloma, tufted angioma, kaposiform hemangioendothelioma, capillary malformations, lymphatic malformations, venous malformations, and arteriovenous malformations. This search was conducted from 7/5/2023 to 3/21/2024.


  • Primary targeted medical therapy for management of bilateral head and neck lymphatic malformations in infants

    by Clare M. Richardson, Kaitlyn Zenner, Catherine Bull, Erika Lutsky, Dana M. Jensen, Victoria Dmyterko, James T. Bennett, Tara L. Wenger, John P. Dahl, Juliana Bonilla-Velez, et al.


  • Acetylsalicylic acid suppression of the PI3K pathway as a novel medical therapy for head and neck lymphatic malformations

    by Juliana Bonilla-Velez, Kathryn B. Whitlock, Sheila Ganti, Kaitlyn Zenner, Chi Vicky Cheng, Dana M. Jensen, Minh-Hang M. Pham, Ryan M. Mitchell, William Dobyns, Randall A. Bly, et al.


  • Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations

    by Kaitlyn Zenner, Chi Vicky Cheng, Dana M. Jensen, Andrew E. Timms, Giridhar Shivaram, Randall Bly, Sheila Ganti, Kathryn B. Whitlock, William B. Dobyns, Jonathan Perkins, et al.

    Lymphatic malformations (LMs) are congenital, nonneoplastic vascular malformations associated with postzygotic activating PIK3CA mutations. The mutation spectrum within LMs is narrow, with the majority having 1 of 3 hotspot mutations. Despite this relative genetic homogeneity, clinical presentations differ dramatically. We used molecular inversion probes and droplet digital polymerase chain reaction to perform deep, targeted sequencing of PIK3CA in 271 affected and unaffected tissue samples from 81 individuals with isolated LMs and retrospectively collected clinical data. Pathogenic PIK3CA mutations were identified in affected LM tissue in 64 individuals (79%) with isolated LMs, with variant allele fractions (VAFs) ranging from 0.1% to 13%. Initial analyses revealed no correlation between VAF and phenotype variables. Recognizing that different mutations activate PI3K to varying degrees, we developed a metric, the genotype-adjusted VAF (GVAF), to account for differences in mutation strength, and found significantly higher GVAFs in LMs with more severe clinical characteristics including orofacial location or microcystic structure. In addition to providing insight into LM pathogenesis, we believe GVAF may have broad applicability for genotype-phenotype analyses in mosaic disorders.


  • Metastatic cellular neurothekeoma in childhood

    by Kaitlyn Zenner, John Dahl, Gail Deutsch, Erin Rudzinski, Randall Bly, Jonathan A. Perkins


  • Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

    by Christina Michailidi, Masamichi Hayashi, Sayantan Datta, Tanusree Sen, Kaitlyn Zenner, Oluwadamilola Oladeru, Mariana Brait, Evgeny Izumchenko, Alexander Baras, Christopher VandenBussche, et al.

    Exposure to toxicants leads to cumulative molecular changes that overtime increase a subject's risk of developing urothelial carcinoma. To assess the impact of arsenic exposure at a time progressive manner, we developed and characterized a cell culture model and tested a panel of miRNAs in urine samples from arsenic-exposed subjects, urothelial carcinoma patients, and controls. To prepare an in vitro model, we chronically exposed an immortalized normal human bladder cell line (HUC1) to arsenic. Growth of the HUC1 cells was increased in a time-dependent manner after arsenic treatment and cellular morphology was changed. In a soft agar assay, colonies were observed only in arsenic-treated cells, and the number of colonies gradually increased with longer periods of treatment. Similarly, invaded cells in an invasion assay were observed only in arsenic-treated cells. Withdrawal of arsenic treatment for 2.5 months did not reverse the tumorigenic properties of arsenic-treated cells. Western blot analysis demonstrated decreased PTEN and increased AKT and mTOR in arsenic-treated HUC1 cells. Levels of miR-200a, miR-200b, and miR-200c were downregulated in arsenic-exposed HUC1 cells by quantitative RT-PCR. Furthermore, in human urine, miR-200c and miR-205 were inversely associated with arsenic exposure (P = 0.005 and 0.009, respectively). Expression of miR-205 discriminated cancer cases from controls with high sensitivity and specificity (AUC = 0.845). Our study suggests that exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of arsenic exposure as well as a maker of early urothelial carcinoma detection. Cancer Prev Res; 8(3); 208–21. ©2015 AACR.